Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allermi is a personalized, multi-ingredient prescription nasal spray developed by Allermi for the treatment of allergic rhinitis and hay fever. The formulation is customized for each patient and typically contains a combination of up to four active ingredients: triamcinolone acetonide (a corticosteroid), azelastine (an antihistamine), oxymetazoline (a micro-dosed decongestant), and an anticholinergic agent. By targeting multiple pathways—including inflammation, histamine receptors, and adrenergic receptors in the nasal vasculature—Allermi aims to provide comprehensive relief from symptoms such as congestion, sneezing, and rhinorrhea. The product is designed by board-certified allergists to optimize efficacy while minimizing side effects like rebound congestion through precise micro-dosing of the decongestant component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allermi.